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1. Introduction 
The hedgehog (Hh) pathway is one of the fundamental signal transduction pathways in 
animal development and is also involved in stem-cell maintenance and carcinogenesis. The 
hedgehog (hh) gene was first discovered in Drosophila, and members of the family have since 
been found in most metazoan. Hh proteins are composed of two domains, an amino-
terminal domain HhN, which has the biological signal activity, and a carboxy-terminal 
autocatalytic domain HhC, which cleaves Hh into two parts in an intramolecular reaction 
and adds a cholesterol moiety to HhN. HhC has a sequence similarity to the self-splicing 
inteins, and the shared region is termed Hint. HhN is modified by cholesterol at its carboxyl 
terminus and by palmitate at its amino terminus in both flies and mammals. The modified 
HhN is released from the cell and travels through the extracellular space. On binding its 
receptor Patched, it relieves the inhibition that Patched exerts on Smoothened, a G-protein-
coupled receptor. The resulting signalling cascade converges on the transcription factor 
Cubitus interruptus (Ci), or its mammalian counterparts, the Gli proteins, which activate or 
repress target genes. The Hh family of morphogens plays important instructional roles in 
the development of numerous metazoan structures (Ingham & McMahon, 2001). The Hh 
ligands, Sonic, Indian and Desert Hh in vertebrates and Hh in Drosophila, signal through 
binding to the membrane receptor Patched (Ptc) (Chen & Struhl, 1996), to reverse the Ptc-
mediated inhibition of signalling by the trans-membrane protein Smoothened (Smo) (Alcedo 
et al., 1996). This allows Smo to activate the intracellular signalling components, resulting in 
stabilization of down-stream transcriptional activator(s) and activation of target genes 
(Hooper & Scott, 1989). Transcription activation is facilited through the Gli family of 
transcription factors in vertebrates (Ingham & McMahon, 2001). Hh signalling can initiate 
cellular growth, division, lineage specification, axon guidance and function as a survival 
factor (Cohen, 2009). Given this range of biological functions, it is not surprising that 
mutations in components of the Hh pathway are associated with both developmental 
defects and tumor progression (Cohen, 2009). Disruption of PTC, which functions as a 
negative regulator of the pathway, is implicated in cancer development in both inherited 
and sporadic cancers. Mutations in PTC and/or SMO trigger inappropriate activation of the 
Hh pathway, and have been identified in tumor types including basal cell carcinoma, 
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rhabdomyosarcoma and medulloblastoma (Taipale & Beachy, 2001). Other studies also 
implicate activated hedgehog signalling as a mediating factor in small-cell lung cancer, 
pancreatic cancer and various digestive tract tumors (Kimberly et al., 2010; Brabletz et al., 
2009). For the increasing types of cancer that are associated with Hh signalling, 
understanding signal transduction will be crucial for identifying potential drug targets and 
devising new therapies. The first purpose of this chapter is review the Hedgehog signalling 
pathway, analyze its components and describe mutations and gene overexpression that 
involve Hh signalling network. The last section addresses the study of Hh pathway as a 
pathological player in the growth of a group of human cancers.  
2. Description of the signalling network 
EVOLUTIONARY ORIGINS 
Hh signal transduction has startling parallels with Wnt signalling, despite the different 
structures of the ligands and the largely distinct components that are dedicated to the 
separate pathways (Nusse, 2003). As both pathways are found throughout the animal 
kingdom, a common ancestral pathway must have been present in the earliest Metazoans. 
Ptc and Hh have distinct evolutionary origins. The Hh protein is comprised of a N-terminal 
signalling domain and a C-terminal catalytic domain. The N-terminal domain is structurally 
related to zinc hydrolases (Hall et al., 1995). The C-terminal catalytic domain of Hh is related 
to inteins, a family of self-splicing proteins (Hall et al., 1995). Hh protein probably arose 
when an intein was appended to the signalling domain; release of the signalling domain 
requires cleavage from the intein and is therefore subject to tight control. In animals, the 
gene for the NPC1 pump was probably duplicated and then diverged to affect the activity of 
a Smo ancestor. The acquisition of loops that bind Hh converted the pump into a signal-
regulated pump. All of these threads woven together indicate that the Hh pathway emerged 
by integration of primordial pathways that are involved in protein splicing, vesicular 
trafficking and nuclear entry. 
SIGNALLING IN VERTEBRATES         
Hh signalling in vertebrates shares many features with that in D. melanogaster (McMahon et 
al., 2003), although clear distinctions have emerged. First, mammalian gene families take the 
place of single genes in D. melanogaster. There are three hh genes in mammals, sonic, Indian 
and desert hedgehog (Shh, Ihh and Dhh); two ptc genes (Ptc1 and Ptc2); and three ci 
homologues (Gli1, Gli2 and Gli3). The three hh genes are expressed in different tissues and at 
different stages of development, and might also have different biological activities. The 
expression and function of Ptc1 is similar to that of D. melanogaster ptc whereas Ptc2 
expression is more restricted and few phenotypes are associated with its loss (Rahnama et 
al., 2004). The post-translational regulation of Ci (D. melanogaster)  and the GLI proteins is 
similar. Each resides in a cytoplasmic pool. In the absence of Hh, each is retained in the 
cytoplasm by Cos2 (KIF7 in vertebrates) and Sufu to limit transcriptional activation 
(Merchant et al., 2004; Rahnama et al., 2004; Paces-Fessy et al., 2004) . Ci, GLI3, and probably 
also GLI2, require PKA and a SCF E3 ubiquitin ligase for processing to a transcriptional 
repressor. However, each GLI protein also has unique roles: GLI3 functions mainly as a 
transcriptional repressor, GLI2 is mainly a transcriptional activator and GLI1 functions only 
as a transcriptional activator. The transcription of Gli1 is induced by Hh signals, which 
creates a positive-regulatory loop that heightens Hh responses. 
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The most important differences between the D.melanogaster and vertebrate Hh pathways 
centre on Smo:  its regulators and its effectors. The sequence of the cytoplasmic tail of Smo is 
highly divergent between vertebrates and D. melanogaster. The entire KIF7 protein from 
zebrafish has some sequence similarity to Cos2, and KIF7 can bind GLI1. Like Cos2, KIF7 is 
required for repression of SHH responses, although it might differ from Cos2 in the degree 
to which it is required for full activation of Hh responses. Another kinesin and two ciliary 
proteins (KIF3a and the intraflagellar transport proteins IFT88 and IFT172) also mediate 
Cos2-like functions in vertebrates, participating in both full repression and full activation of 
Hh responses (Huangfu et al., 2003). Although it is likely that some, or all, of these four 
proteins fulfil the biochemical role(s) of Cos2, this remains to be tested. Some vertebrate Hh 
pathway genes have no known orthologues in D. melanogaster; some have orthologues, the 
role of which in Hh signalling has not been explored; and some have known orthologues 
with other functions. Missing in metastasis (MIM), which is also known as BEG4, is an actin-
binding protein that potentiates GLI dependent transcriptional activation (Callahan et al., 
2004). Positive vertebrate regulators of the Hh signalling pathway that have no known 
orthologues in flies include megalin, which belongs to the low-density lipoprotein (LDL)-
receptor-related family and binds SHH41, and iguana, a zinc-finger protein that promotes 
the nuclear localization of GLI1 (Wolff et al., 2004). Negative regulatory factors distinguish 
vertebrate Hh signalling as well: FKBP8 is a transcription factor that antagonizes SHH 
action in the nervous system (Bulgakov et al., 2004), whereas SIL is a cytosolic protein that 
seems to functions downstream of PTC (Izraeli et al., 2001). Rab23 is a regulator of vesicular 
trafficking and a negative regulator of the Hh response (Eggenschwiler et al., 2001). Shifted 
(Shf) is a secreted protein and is the D. melanogaster orthologue of human Wnt inhibitory 
factor (WIF). Shf facilitates Hh signalling by binding Hh and heparansulphate 
proteoglycans, whereas WIF binds WNT proteins and facilitates Wnt signalling (Glise et al., 
2005). At least some of the apparent differences between phyla are the result of the 
functional convergence of non-homologous genes and proteins. The mammalian membrane 
glycoprotein Hh-interacting protein (HIP) and D.melanogaster Pxb have no sequence 
similarity, but they might fulfil the same function. Each is a transcriptional target of Hh and 
each participates in a negative- feedback loop that attenuates Hh responses (HIP through 
direct binding to SHH) (Inaki et al., 2002). The larger question of whether the core of the 
signal transduction apparatus works in the same manner in the two phyla remains to be 
elucidated. 
Hh acts to regulate the three Gli proteins in different ways. Gli1 appears to act as an 
activator to mediate and/or amplify the Hh response and is transcriptionally induced by Hh 
signalling in all context studied. The situation with Gli2 and Gli3 is more complex. Hh 
signalling represses both the transcription of Gli3 and the proteolytic formation of Gli3 
repressors. However, the function of Gli2, and probably Gli3, can be positive or negative in 
relation to Hh signalling in different situations (Ingham & McMahon, 2001). Therefore, Hh 
pathway function relies both on Gli activating function and on inhibiting Gli repressor 
formation (Ruiz i Altaba, 2002). 
HEDGEHOG AS A CONCENTRATION-DEPENDENT SIGNAL 
One of the most intriguing questions regarding Hh signaling is how Smo signalled to the 
HSC to regulate Ci. Although Smo shares homology with G-Protein Coupled Receptors 
(GPCRs), current evidence argues against the involvement of a traditional G-protein. For 
example, the Smo mutants SmoC and FFS, which lack the domains one would expect to 
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Fig. 1. Diagram schematizes the generalized regulation of the Gli proteins by proteolisis. 
Zic2 encodes a small protein with a GLI-type zinc-finger domain that may act as a repressor 
of transcription. Variations of these subjects might occur in different organs. 
interact with a G-protein, are still capable of propagating Hh signalling (Hooper, 2003). 
Additionally, reducing the expression of all known Drosophila heterotrimeric GTP binding 
proteins, through use of RNA interference (RNAi), had little effect on Hh responses in 
cultured cells (Lum et al., 2003). This lack of compelling evidence for G-protein involvement 
in the Hh pathway led multiple groups to look for direct interactions between Smo and HSC 
components. Several recent publications, demonstrating an interaction between the carboxyl 
terminal tail of Smo and the cargo domain of Cos2, have begun to shed light onto the 
mechanistic events involved in Smo-mediated signaling to the HSC (Lum et al., 2003; Ruel et 
al., 2003; Jia et al., 2003; Ogden et al., 2003). In spite of there are some differences in the 
published studies, there seems to be a consensus on the following points: (1) Smo binds 
Cos2 directly; (2) the interaction is necessary for functional Hh signaling; (3) Cos2 appears to 
tether significant amounts of Fu to Smo, while Ci and Su(fu) binding are not as obvious. A 
requirement for direct Smo–Cos2 binding in signal transduction is most obvious when 
examining target gene expression following loss of interaction. The Smo carboxyl-terminal 
tail was demonstrated to contain the Cos2 interaction domain (Jia et al., 2003; Ogden et al., 
2003). Over-expression of this domain appears to have a dominant negative effect, resulting 
in a dose dependent loss of reporter gene expression. Similarly, over-expression of Smo 
proteins lacking the Cos2 binding domain and/or Cos2 constructs lacking the Smo binding 
domain demonstrate compromised Hh responses (Lum et al., 2003; Ruel et al., 2003; Jia et 
al., 2003) . These results clearly demonstrate a requirement for Cos2–Smo interaction for 
proper Hh signal transduction. Additionally, the amount of membrane associated 
Hedgehog Signalling Complex (HSC) appears to decrease in response to Hh (Ruel et al., 
2003). This observation is seemingly inconsistent with the model whereby the Smo/Cos2 
association remains constant or even increases. To explain this apparent paradox was 
proposed (Ogden et al., 2004) that there may be two distinct HSCs, one involved in 
converting Ci into its repressor form, HSC-R, and one involved in converting Ci into its 
activated forms, HSC-A. In the absence of Hh, HSC-R is on and HSCA is off, while in 
response to maximal Hh, HSC-A is turned on and HSC-R is turned off. In between this two 
switch system, numerous intermediates exist.  
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Fig. 2. Diagram shows how the Hh gradient regulates HSC activator and repressor 
functions. In the without Hg signalling HSC-R is producing Ci75 and HSC-A is inactive. In 
the central cell, HSC-A is producing Ciact, which may be acting in presence of lower Ci75. In 
the right cell, the greatest amount of Hh is received, HSC-A is maximally activated by Smo 
and HSC-R is completely silence. 
It is known that graded sonic hedgehog activity patterns the ventral neural tube. Five 
distinct neuronal cell fates are specified in the ventral half of the neural tube in response to a 
gradient of SHH (Jessell, 2000). The cells of the floor plate respond to the highest 
concentration of SHH that is secreted by the notochord by becoming glial cells, which, in 
turn, begin to secrete SHH themselves. The remaining neural tube cells choose between 
various ventral neural fates that are specified by different thresholds of SHH signalling. 
LOCALIZATION AND FUNCTION 
Hh proteins are synthesized as precursor proteins (about 400-460 amino acids long) and 
comprise several different motifs and domains: a signal peptide for protein export, a 
secreted amino-terminal HhN (Hedge) domain that acts as a signalling molecule, and an 
autocatalytic carboxy-terminal HhC (Hog) domain that contains a Hint module. Multiple 
sequence alignments of the HhN and HhC domains defining the conserved residues and 
features have been presented in (Bürglin, 2008). HhC binds cholesterol in the sterol 
recognition region (SRR) (Beachy et al., 1997). The catalytic activity of the Hint module 
cleaves Hh into two parts and adds the cholesterol moiety to the carboxyl terminus of HhN. 
Figure 2 outlines the Hh signalling patway. 
In the figure 2 Hh is targeted to the endoplasmic reticulum by its signal peptide, is 
palmitoylated at its amino terminus by Rasp/Skinny Hedgehog (Ski), and autoprocessed. 
Lipidated HhN (M-HhN) is released by Dispatched (Disp) and forms multimers or 
associates with lipoproteins (LP) in the extracellular environment (Cohen, 2003). Several 
molecules can interact with M-HhN and propagate or modulate its trafficking: the Dally-like 
protein (Dlp) that is modified by the heparan sulfate (HS) polymerases Tout-velu (Ttv), 
Sister of tout-velu (Sotv), and Brother of tout-velu (Botv), all members of the EXT family; the  
Hedgehog-interacting protein (Hip); and the Growth-arrest specific1 (Gas1) protein. Hip 
and Gas1 are not present in Drosophila. Megalin (Meg) is most probably involved in the 
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Fig. 3. A schematic Hh signalling pathway, obtained from combined Drosophila and 
mammalian data.  
recycling of M-HhN. Ihog is thought to function as co-receptor for M-HhN. M-HhN acts as 
an antagonistic ligand that represses the function of the receptor Patched (Ptc), a 12- 
transmembrane protein related to Disp. Binding of M-HhN to Ptc results in internalization. 
Smoothened (Smo) is a seven-pass membrane receptor, which is the key for the transmission 
of the signal to the nucleus in the Hh pathway. Smo is inhibited by Ptc when not bound by 
M-HhN. If the inhibitory function of Ptc is released by M-HhN, Smo can translocate to the 
plasma membrane or - in mammals - to the primary cilium, and active Smo is 
phosphorylated. Ptc may secrete pro-vitamin D3 or related compounds (D3) to inhibit Smo. 
Conversely, oxysterols (Oxy) can indirectly activate Smo (Eaton, 2008; Rohatgi et al., 2007). 
The Hh pathway downstream of Smo displays some important differences between 
Drosophila and mammals. In Drosophila, when Smo is active, the signal passes through a 
complex comprising the kinesin-like molecule Costal 2 (Cos2), Fused (Fu), Suppressor of 
fused (Su (fu)) and Cubitus interruptus (Ci), leading to the release of Ci, which can then 
enter the nucleus to promote transcription. When Smo is inhibited, the Cos2/Fu/Su (fu)/Ci 
complex remains associated with microtubules, Ci is phosphorylated and is cleaved by 
Cos2. The Ci fragment now acts as a transcriptional repressor. In mammals, the targeting of 
Smo to primary cilia is essential for signal transduction. No obvious equivalents of Cos2 and 
Fu exist in mammals. Instead, Su (fu) has a more prominent role in inhibiting the pathway. 
Gli1, Gli2, and Gli3 are the mammalian homologs of Ci; Gli1 and Gli2 activate transcription 
when Smo is active, whereas Gli3 is processed and becomes a repressor when Smo is 
inhibited.  
In animal development, the secreted M-HhN moiety functions as a morphogen. The Hh 
signalling pathway plays many important roles in development, including conferring 
segment polarity on the body segments and patterning the wing in Drosophila, and 
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patterning the neural tube in mammals (Dessaud et al., 2008; Varjosalo & Taipale, 2008) . Hh 
is also required for stem-cell maintenance, and mutations in the pathway lead to cancer. 
Increased activity of the pathway causes basal cell carcinoma and medulloblastoma (Beachy 
et al., 2004; Jacob & Lum, 2007). For example, insufficient Ptc function leads to Gorlin 
syndrome in humans, one feature of which is an increased risk of basal cell skin cancer. 
In mammals, Shh, Dhh, and Ihh have partially redundant functions. Shh is the most widely 
expressed of the three paralogs, and regulates development from embryo to adult. Key roles 
are in patterning the neural tube: Shh is first expressed in the notochord, and later in the 
floor plate of the neural tube, where it produces a gradient of activity in the ventral neural 
tube. Shh is also expressed in the zone of polarizing activity of the limb buds and is 
important for limb and digit formation. Other roles of Shh include inner ear, eye, taste bud, 
and hair follicle development. Ihh is expressed in the primitive endoderm and is required 
for bone growth and pancreas development. Shh and Ihh both play roles in cardiovascular 
development. Dhh is expressed in the gonads, and Dhh-mutant males are sterile (Bijlsma et 
al., 2006; Dessaud et al., 2008; Varjosalo & Taipale, 2008). 
SECRETION, TRAFFICKING AND SPREADING OF HEDGEHOG 
Dispatched is necessary for Hh secretion (Burke et al., 1999). Dispatched contains 12 
transmembrane domains and is related to the resistance-nodulation division (RND) family 
of bacterial proton-driven pumps (Ma et al., 2002). Bacterial proteins of the RND family use 
a proton gradient to transport multiple small lipophilic molecules across the membrane 
bilayer. The two other metazoan members of this family include the Hh receptor Patched, 
and the protein encoded by the Niemann–Pick type C1 (NPC1) disease gene, which 
promotes cholesterol efflux from late endosomes. Members of the RND family: Patched, 
Dispatched and NPC1, contain two related copies of a signature domain with six 
transmembrane-spanning regions. Mutations in Dispatched which disturb conserved 
residues that are important for the function of bacterial transporters, also prevent Hh release 
(Ma et al., 2002), consistent with the hypothesis that Dispatched can transport a small 
molecule across the bilayer. A fragment of the signature RND domain, called a sterol-
sensing domain, is also shared with other proteins that are involved in sterol metabolism. 
The sterol-sensing domain of HMGCoA reductase (the rate-limiting enzyme in cholesterol 
biosynthesis) regulates its stability in response to cholesterol. The sterol-sensing domain of 
SCAP [sterol-regulatory-element-binding protein (SREBP) cleavage-activating protein] 
responds to cholesterol levels by altering membrane trafficking and the cleavage of the 
membrane-associated transcription factor SREBP, which regulates the transcription of genes 
that are involved in sterol metabolism (Chang et al., 2006). Whether Dispatched itself 
responds to sterol levels is not known, and its precise function in Hh release has not yet 
been determined. The mechanism of Dispatched to respond to the levels of sterol and how 
Hh is released has not yet been determined. 
Biochemical fractionation of imaginal discs from D. melanogaster larvae shows that, although 
most lipid-modified Hh will form pellets with cell membranes, Hh molecules that remain in 
the supernatant are almost entirely associated with lipoprotein particles (Panáková et al., 
2005). It will be interesting to determine whether the cholesterol-dependent Hh multimers 
that are secreted by tissue-culture cells might reflect the association of Hh with serum-
derived lipoproteins, or whether multimer formation is a completely distinct mechanism for 
Hh release. Lipoproteins comprise a phospholipid monolayer that surrounds a core of 
esterified cholesterol and triglyceride. Lipid modifications, such as the addition of 
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cholesterol, palmitate and glycosyl phosphatidylinositol (GPI), that target proteins to the 
exoplasmic face of the plasma membrane should fit equally well into the outer phospholipid 
monolayer of lipoproteins. Indeed, D. melanogaster lipophorin particles also bind to the 
morphogen molecule Wingless, which is palmitoylated twice and to several GPI-linked 
proteins (Panáková et al., 2005; Eugster et al., 2007).  
Two mechanisms are hypothesized for Hh release in wing discs: a long-range mechanism 
that depends on lipophorin and a shortrange mechanism that is lipophorin independent. 
Whether any of the mammalian Hh proteins bind to low-density lipoprotein (LDL) or high-
density lipoprotein (HDL)-type particles is unknown, although this would be interesting to 
investigate. Cholesterol modification clearly has an important influence on Hh trafficking. 
The 19 kDa N-terminal Hh domain can be artificially generated in the absence of cholesterol 
modification by the simple expedient of stop codon insertion or C-terminal domain 
deletions (Porter et al., 1996). This altered protein, termed HhN, is secreted in a Dispatched-
independent manner (Burke et al.,1999), does not form multimeric complexes (Gallet et al., 
2006; Chen et al., 2004; Feng et al., 2004), and is distributed differently in both producing 
and receiving cells (Gallet et al., 2003; Callejo et al., 2006). Although HhN has been reported 
to spread further, it does not seem to signal as efficiently as cholesterol modified Hh (Porter 
et al., 1996; Gallet et al., 2006; Li et al., 2006). The anchors probably interact, either with each 
other (when Hh is organized as micellar multimers) or with the outer phospholipid 
monolayer of a lipoprotein. Interaction with heparan sulphate proteoglycans (HSPGs) 
provides a likely explanation for the continuing association of Hh micelles or Hh– 
 
Fig. 4. Possible carriers for Hedgehog release. Hh (blue) is covalently linked to cholesterol 
(red) and palmitate (green). The interaction of the lipid moieties with each other promotes 
the formation of Hh multimers. Finally, a lipoprotein consists of an outer phospholipids 
monolayer (brown) that surrounds a core of sterified cholesterol (EC) and triglyceride (TG). 
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lipoprotein complexes with tissue. Lipid-modified Hh does not enter tissue that cannot 
synthesize heparan sulphate (Han et al., 2004). Recent work suggests that lipoproteins 
interact physically with HSPGs in D. melanogaster wing discs (Eugster et al., 2007). Hh that 
has interacted with lipoproteins through lipid anchors might therefore be restricted to tissue 
through these lipoprotein–heparan sulphate interactions. This would be consistent with the 
observation that only lipid modified Hh is dependent on HSPGs in orders to associate with 
tissue. Direct binding of Hh to HSPGs might also provide tissue affinity. In this case, Hh 
multimerization might also promote HSPG binding by increasing the local concentration of 
heparan sulphate-binding sites on Hh. 
TRANSCRIPTIONAL REPRESSION OR ACTIVATION IN HEDGEHOG RESPONSE 
Hedgehog responsive changes in gene expression are mediated by the zinc finger 
transcription factor Ci, which can assume repressing and activating forms. The represing 
form, CiR, represents an N-terminal proteolytic fragment that retains the zinc finger-
mediated DNA binding specificity of Ci but lacks nuclear export signals, a cytoplasmic 
anchoring sequence, and a transcriptional activation domain. For some genes, such the 
universal Hh pathway target ptc, expression requires loss of CiR and the positive action of 
Ci. So the expression of Hh pathway targets depends on regulation of Ci processing and 
localization. 
Formation of CiR requires phosphorylation of specific serine-threonine residues by cyclic 
adenosine monophosphate (cAMP) dependent protein kinase. The phosphorylated form of 
Ci appears to be a substrate for a proteolytic processing reaction that requires function of the 
proteasome and of Slimb (Slmb), an F-box-containing E3 ubiquitin ligase component. Ci 
phosphorylation and processing may be mediated by Cos2 scaffolding of kinases with Ci, 
although direct associations of these kinases with Cos2 or Ci have not yet been reported. 
(Lum & Beachy, 2004). 
 
 
Fig. 5. Representation of Ci functional domains and motifs. They are labelled by amino 
acid numbers (in parenthesis). Phosphorylation sites are indicated, they are required for 
initiation of Ci proteolytic processing. Pathway activating functions of Ci are associated 
with full-length Ci (green line) whereas repressor functions are associated with the 
proteolytically processed form CiR (red line). 
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The kinase(s) that phosphorylate Fu and Cos2 remain to be identified and the significance of 
their phosphorylation remains to be determined. Hh also facilitates the association of a small 
population of Sufu molecules with the Cos2-Fu-Smo complex. A genetic analysis indicates 
that Fu phosphorylates Sufu, but biochemical evidence for this lacking. One possibility is 
that high concentrations of Hh promote Smo phosphorylation and dimerization. This 
activates the Fu kinase that is associated with Complex I, which then phosphorylates Sufu to 
release CiA. Curiously, the full spectrum oh Hh responses is seen in D.melanogaster in the 
absence of Sufu, if Cos2 regulation is normal. So there must be an alternative pathway to 
CiA that involves Cos2 rather than Sufu that in vertebrates remain to be determined (Lum et 
al., 2003; Stegman et al., 2000). 
 
Fig. 6. Ilustration of a model for signalling by Smoothened (Smo) and Costal-2 (Cos-2). Smo 
can assume three distinct states. Under Patched influence, Smo adopts an inactive 
conformation. This form of Smo distributes between endosomes, where it can associate with 
Cos-2, and lysosomes, where it is degraded. The remaining Cos2 recruits protein kinase A 
(PKA), casein kinase I and glycogen synthase kinase-3 to Ci, which enables phosphorylation 
of Cubitus interruptus (Ci) and its subsequent processing to the transcriptional repressor 
form (CiR). When the influence of Ptc decreases, the transmembrane helices of Smo are 
rearranged, which exposes a new surface in its cytoplasmic tail. This surface causes PKA, 
CKI and GSK3 to dissociate from Cos2, so that Ci is no longer phosphorylated or processed 
to CiR. Smo is phosphorylated instead, and it assumes its third state. Phosphorylated Smo 
traffics to the surface, rather than to lysosomes for degradation. Smo concentrations rise and 
Smo assembles a modified signalling complex that promotes the phosphorylation of Fused 
(Fu) and Cos2. Phosphorylated Cos2 dissociates from membranes and recruits Fu to Sufu 
(Suppressor of Fused), which produces the activated form of Ci (CiA), probably through 
phosphorylation of Sufu phosphorylated (Ogden et al., 2004). 
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3. Hedgehog signalling in human disease 
In addition to functioning in the embryo, Hh proteins and Hh signal-transduction 
components are expressed in postnatal and adult tissues, suggesting that they function in 
the mature organism. Defects in Hh signalling could, therefore, affect both the human 
embryo and the adult (Ruiz i Altaba, 2002). 
THE CANCER STEM CELL THEORY  
A great deal of interest has focused on mutation or aberrant regulation in stem cells as a key 
factor in carcinogenesis. A link between stem cells and cancer is not a new concept (Sell, 
2004). Subsequently it was widely accepted that the initiation and progression of 
malignancy is a multi-step process, driven by numerous genetic changes that result in the 
transformation of normal cells into malignant cells. Environmental factors apply 
evolutionary pressure on the tumor, which leads to selection of clones with a greater 
capacity to survive, grow and metastasise. In this theory, any normal cell undergoing 
sufficient genetic alterations to result in its unregulated proliferation may become a tumor-
initiating cell. The observed heterogeneity of many tumors is due to the development and 
expansion of numerous subclones. This clonal evolution theory is believed to explain the 
ultimate insensitivity of many tumors to chemotherapy, as clones with the ability to export 
the drug, or which lack key components of metabolic pathways targeted by the drug, are 
positively selected for their ability to evade death. The identification of stem cells in a range 
of tissues and organs and a greater understanding of their biology has again focused 
attention on the “stem cell theory of cancer” which proposes that malignancy arises from the 
transformation of a normal tissue stem cell. The cancer stem cell theory hypothesises that, 
analogous to stem cells in normal tissues, there are a small proportion of cells within tumors 
that have stem cell properties giving rise to progeny which may show heterogeneous patterns 
of differentiation and form the bulk of the tumor mass. The existence of cancer stem cells is 
thought to explain the failure of chemotherapy and other treatments to eradicate metastatic 
disease. With the continuing identification of stem-like cells within increasing numbers of 
malignancies, it is obviously that a new approach to treatment is required, one which directly 
targets the cancer stem cells in association with more traditional approaches that affect tumor 
bulk. These highly tumorigenic cells, also known as cancer stem cells, have the ability to self-
renew and differentiate into multiple lineages. Cancer stem cells have been isolated from 
human tumors involving the breast, lung, colon, pancreas, prostate, skin, head/neck and 
brain. Experimental and clinical research indicates that cancer stem cells, as well as cells from 
solid tumors, are resistant to chemotherapy and radiation therapy. Therapeutic approaches are 
in development to block embryonic pathways that play a role in cancer stem cells, including 
Notch, sonic hedgehog and Wnt. 
HEDGEHOG IN CANCER 
Defects in Hh signalling pathway have long been known to be associated with human 
congenital disease with the loss of one copy of Shh resulting in holoprosencephaly (Roessler 
et al., 1996). More recently has been documented that aberrant Hedgehog signalling is 
associated with the development and progression of a wide range of human malignancies. 
Mutations such as Ptch1 and Smo are associated with medulloblastoma, basal cell carcinoma 
and rhabdomyosarcoma. Aberrant activation of Hh signalling is also suggested to play a 
role in other cancers that have no known mutational basis, such as glioma, breast, 
esophageal, gastric, pancreatic, prostate, chondrosarcoma and small-cell lung carcinoma. In 
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these tumors the Hh pathway abnormalities are called ligand-dependent and were 
described first in lung (Watkins et al., 2003) and then in gastrointestinal tract and pancreatic 
carcinoma (Berman et al., 2003), which show no mutation in Hh pathway genes but are 
characterised by upregulation of the expression of Hh ligand which is also though to 
include autocrine and paracrine mechanism of activation. There are two proposed models to 
explain how Hh ligands promote tumor growth: one postulates that Hh ligands produced 
by cancer cells and/or their stromal environment maintain secreted stem cell renewal within 
the tumor (Jiang & Hui, 2008); the second proposes that Hh ligands secreted by the tumor 
may act on nearby stromal cells, resulting in pathway activation in the stromal 
microenvironment that promotes tumor growth (Yauch et al., 2008). 
HEDGEHOG SIGNALLING IN CANCER STEM CELLS 
Data from many human tumors including glioblastoma, breast cancer, pancreatic 
adenocarcinoma, multiple myeloma, and chronic myeloid leukemia (CML) have suggested 
that Hh signaling moderates cancer stem cells (CSC). Self-renewal of CSC is required for 
maintenance of the malignant clone, and reports studying mouse models of CML have 
provided evidence that Hh signaling regulates this property (Dierks et al., 2008; Zhao et al., 
2009). Active Hh signalling pathway has also been identified in glioblastoma CSCs, and 
pathway inhibition with cyclopamine or siRNA directed against pathway components 
results in the loss of tumorigenic potential (Clement et al., 2007). In breast cancer, pathway 
activation in CSCs using Hh ligand and GLI1 or GLI2 expression or inhibition with 
cyclopamine or siRNA directed against GLI1 or GLI2 alters the expression of BMI-1 (Liu et 
al., 2006). In multiple myeloma, CSCs that phenotypically resemble normal memory B cells 
have been found to display relatively higher levels of Hh signalling than the mature plasma 
cells constituting the tumor bulk (Peacock et al., 2007). So, HH signalling may dictate CSC 
fate decisions that include self-renewal and differentiation possibly by generation of a 
malignant niche (LaBarge, 2010). Data from multiple myeloma demonstrate that Hh 
signaling can act through multiple signaling modes within the same cancer and can mediate 
interactions between CSCs, differentiated tumor cells and the microenvironment. 
Aditionally to tumor formation, CSCs have been implicated in disease progression and the 
development of metastasis in solid tumors (Rasheed et al., 2010), and Hh signaling may play 
a critical role in this process similar to the Notch and Wnt pathways in cancer. In colon 
carcinomas, Hh signaling has been found to be preferentially activated within CSCs as 
evidenced by relatively higher expression of GLI1, GLI2, PTCH1, and HIP within this 
cellular compartment (Varnat et al., 2009). Moreover, the relative expression of these 
pathway components as well as the target gene SNAIL1, which is associated with the 
epithelial-to mesenchymal transition (EMT) and implicated in metastasis, increases in CSCs 
with disease stage.  
INHIBITORS OF HEDGEHOG SIGNALLING 
It has been accepted that altered Hh signalling contributes to the development of up to one 
third of all human malignancies (Beachy et al., 2004) and so there is a great interest in 
therapeutic inhibition of the pathway, with a number of inhibitors in clinical trials. The first 
inhibitor of the Hedgehog pathway identified was cyclopamine (Cooper et al., 1998), 
Cyclopamine is a small molecule inhibitor of Smoothened, and a number of compounds 
have been identified or synthesized which have similar mechanisms of action. To inhibition 
of the pathway several approaches have been developed: 
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1. Prevention of Hh ligand binding to Ptch receptor. 
2. Inhibition of Smoothened via cyclopamine and related compounds. Much of the 
preclinical and clinical trial work on Hh inhibitors undertaken to date focuses on 
inhibitors of Smo. 
3. Inhibiotrs of Gli transcription. 
 
 
Fig. 7. Ilustration of a schematic representation of the pathway in a normal cell, a cancer cell 
and the action of inhibitors over the Hedgehog pathway. 
DEVELOPING IMPROVED HEDGEHOG THERAPIES 
In adulthood, the Hh signalling pathway is silenciated in the great majority of cells. 
However, there have been an increasing number of reports over the past decade 
documenting the implication of the Hh pathway in human diseases, such as cancer. For 
these reasons, Hh pathway antagonists have been sought after as potential new treatments 
for cancer. The theory that many tumors arise from a small number of cancer stem cells 
(CSCs) has recently gained strength with some landmark studies that point to the existence 
of a discrete population of slowly dividing tumor cells capable of self-renewal and 
differentiation along multiple lineages. The control of these processes in cancer stem cells is 
thought to be regulated by a small number of signaling pathways as Hh, Wnt, and Notch , 
and growing evidence suggests that some of these pathways are deregulated, allowing for 
their abnormal expansion and the formation of cancer. 
These Hh, Wnt, and Notch pathways might be interconnected and ultimately lead  to the 
regulation of stem-cell self-renewal via Bmi-1 transcription factor (Liu et al., 2006). These 
data suggest additional possible uses for inhibitors of pathway such as Hh. The outcome of 
Hh signaling varies according to the receiving cell type, but it can include expression of a 
variety of cell-specific transcription factors mediating different developmental fate response: 
upregulation of D-type cyclins, resulting in cell proliferation; upregulation of anti-apoptotic 
proteins such as Bcl-2, mediating cell survival; production of vascular endothelial growth 
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factor (VEGF) and angiopoietins regulating angiogenesis; and transcription of SNAIL, 
initiating the epithelial-mesenchyme transition (EMT) in metastasis. It is, therefore, not 
surprising that deregulated Hh signalling can lead to a variety of cancers. 
Three basic models have been proposed for Hh pathway activity in cancer (Rubin & de 
Sauvage, 2006). The type I cancers, which harbour pathway-activating mutations, such as 
basal carcinomas (BCCs), medulloblastomas, and rhabdomyosarcomas. Type II cancers, are 
ligand dependent and autocrine/juxtacrine, meaning that Hh is both produced and 
responded to by the same/neighbouring tumor cells, including breast, upper 
gastrointestinal tract, colorectal, prostate and lung tumors. Type III cancer, are also ligand 
dependent but paracrine, in that Hh produced by the tumor epithelium is received by cells 
in the stroma, which feed other signals back to the tumor to promote its growth or survival. 
The clinical reality is that the majority of cancer patients present with locally or distant 
metastatic, surgically inoperable disease. Therefore, the development of more potent 
therapies for advanced/metastatic human cancers mandates great urgency. Multiples line of 
evidence support the idea that Hedgehog signalling has a role in the maintenance and 
progression of many human cancers. First, studies involving global sequencing analysis 
have identified the Hh pathway as one of the core signalling pathway of human cancers; 
second, the inhibition of Hh enhanced survival in genetically engineered mouse model of 
cancers; third, blockade of the Hh pathway eliminates cancer stem cells. 
Intervention of the Hh pathway has provided a therapeutic opportunity for treatment of 
malignancies. Effective inhibition of the Hh pathway can be achieved at the level of ligands 
by using anti-Hh antibodies, or through downstream effectors molecules, such as Smo, with 
small-molecule antagonist (Evangelista et al., 2006). 
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